Article
Full Access
Oestrogens reconsidered
Philip H. Smith MD,
Corresponding Author
Philip H. Smith MD
Department of Urology, St lames's University Hospital, Leeds, United Kingdom
St. James's University Hospital, Beckett Street, Leeds LS9 7TF, United KingdomSearch for more papers by this authorPhilip H. Smith MD,
Corresponding Author
Philip H. Smith MD
Department of Urology, St lames's University Hospital, Leeds, United Kingdom
St. James's University Hospital, Beckett Street, Leeds LS9 7TF, United KingdomSearch for more papers by this authorAbstract
Oestrogen therapy or orchidectomy reigned supreme for the treatment of metastatic prostatic cancer for almost 40 years. In the last 15 years many alternative agents have been tested alone and more recently in combination. This contribution evaluates the results of some of these newer therapies considering relief of symptoms, toxicity, quality of life, survival, and benefit to the community. The results are compared with those of oestrogen therapy and with the way in which such treatment might be amended in light of more modern knowledge. © 1995 Wiley-Liss, Inc.
References
- 1 Huggins C, Hodges CV: Studies on prostatic cancer I. The effect of castration of estrogen and the androgen inject on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1: 293–297, 1941.
- 2 Huggins C, Scott WW, Hodges CV: Studies on prostate cancer III. The effects of fever, deoxycorticosterone and of estrogen on clinical patients with metastatic carcinoma of the prostate. J Urol 46: 997–1006, 1941.
- 3 Ferguson JD: Cancer of the prostate II. B M J 4: 539–540, 1970.
- 4 Veterans Administration Cooperation Urological Research Group: Treatment and survival of patients with cancer of the prostate. Surg Gynecol Obstet 124: 1011–1017, 1967.
- 5
Byar DP:
The Veterans Administration Cooperative Urological Research Group's studies of cancer of the prostate.
Cancer
32: 1126–1130,
1973.
10.1002/1097-0142(197311)32:5<1126::AID-CNCR2820320518>3.0.CO;2-C CAS PubMed Web of Science® Google Scholar
- 6 Byar DP: Review of the Veterans Administration studies of cancer of the prostate and new results concerning treatment of stage I and II tumours. In M Pavone-Macaluso, PH Smith, F Edsmyr (eds): “ Bladder Tumours and Other Topics in Urological Oncology.” New York: Plenum Press, 1978, 471–492.
- 7 Pavone Macaluso M, de Voogt HJ, Viggiano G, et al: Comparison of diethylstilboestrol, cyproterone acetate and medroxy-progesterone acetate in the treatment of advanced prostate cancer: final analysis of a randomised phase III trial of the EORTC GU group. J Urol 136: 624–631, 1986.
- 8 Smith PH, Suciu S, Robinson MRG, et al: A comparison of the effect of diethylstilboestrol with low dose estramustine phosphate in treatment of advanced prostate cancer: final analysis of a phase III trial of the European Organisation for Research on the treatment of cancer. J Urol 136: 619–623, 1986.
- 9 de Voogt HJ, Smith PH, Pavone Macaluso M, et al: Cardiovascular side effects of diethylstilboestrol, cyproterone acetate, medroxyprogesterone acetate and estramustine phosphate used for the treatment of advanced prostatic cancer: results from European Organisation for Research on Treatment of Cancer Trials 30761 and 30762. J Urol 135: 303–307, 1956.
- 10
Robinson MRG:
A further analysis of European Organisation for Research and Treatment of Cancer Protocol 30805. Orchidectomy versus Orchidectomy plus cyproterone acetate versus low dose diethylstilboestrol.
Cancer (suppl)
72: 3855–3857,
1993.
10.1002/1097-0142(19931215)72:12+<3855::AID-CNCR2820721718>3.0.CO;2-I CAS PubMed Web of Science® Google Scholar
- 11
Klijn JGM,
de Voogt HJ,
Studer VE, et al:
Short term versus long term addition of cyproterone acetate to Buserelin therapy in comparison with orchidectomy in the treatment of metastatic prostatic cancer.
Cancer (suppl)
72: 3858–3862,
1993.
10.1002/1097-0142(19931215)72:12+<3858::AID-CNCR2820721719>3.0.CO;2-6 CAS PubMed Web of Science® Google Scholar
- 12 Denis LJ, Carneiro de Moura JL, Bono A, et al: Goserelin acetate and fiutamide versus bilateral orchiectomy: a phase III EORC Trial (30853). Urology 42: 119–129, 1993.
- 13 Crawford ED, Eisenberger MA, McLeod DG, et al: A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. New Engl J Med 321: 429–424, 1989.
- 14 Smith PH: In MC Slevin, MJ Staquet (eds): “ Cancer of the Prostate in Randomised Trials in Cancer: A Critical Review by Sites.” New York: Raven Press, 1986, 605–630.
- 15 Kelly WK, Scher HI: Prostate specific antigen decline after antiandrogen withdrawal: The Flutamide Withdrawal Syndrome. J Urol 149: 607–609, 1993.
- 16 Dupont A, Gomez JL, Cusan L, et al: Response to Flutamide withdrawal in advanced prostate cancer in progression under combination therapy. J Urol 150: 908–913, 1993.
- 17 Sartor O, Cooper M, Weinberger M, et al: Surprising activity of Flutamide withdrawal, when combined with Aminoglutethimide, in treatment of “hormone-refractory” prostate cancer. J Natl Cancer Inst 86: 3: 222–227, 1994.
- 18
Denis L,
Murphy GP:
Overview of phase III trials on combined androgen treatment in patients with metastatic prostate cancer.
Cancer
72(suppl 12):
3888–3895,
1993.
10.1002/1097-0142(19931215)72:12+<3888::AID-CNCR2820721726>3.0.CO;2-B CAS PubMed Web of Science® Google Scholar
- 19 Antiplatelet Trialists Collaboration: Collaborative overview of randomised trials of antiplatelet therapy. I: Prevention of death, myocardial infarction and stroke by prolonged anti-platelet therapy in various categories of patients. B M J 308: 81–106, 1994.
- 20 Antiplatelet Trialists Collaboration: Collaborative overview of randomised trials of antiplatelet therapy II. Maintenance of vascular graft or arterial patency by antiplatelet therapy. B M J 308: 159–168, 1994.
- 21 Antiplatelet Trialists Collaboration: Collaborative overview of randomised trials of antiplatelet therapy HI. Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. B M J 308: 235–246, 1994.
- 22
Seal US,
Doe RP,
Byar DP, et al:
Response of plasma fibrino-gen and plasminogen to hormonal treatment and the relation of pretreatment values to mortality in patients with prostatic cancer.
Cancer
38: 1108–1117,
1976.
10.1002/1097-0142(197609)38:3<1108::AID-CNCR2820380310>3.0.CO;2-L CAS PubMed Web of Science® Google Scholar
- 23 Steg A, Benott G, Limouzin-Lamotte A, Mahoudeau et al.: Cancer de la prostate: effects metaboliques des beta-estradiol par voie percutanee. La Nouvelle Presse 8: 3801–3802, 1979.
- 24 Hasui Y, Marutsuka K, Nishi S, et al: The relationship between cardiovascular complications of estrogen therapy and fibrinolysis in patients with prostatic cancer. Prostate 21: 35–39, 1992.
- 25 Andersson L, Benin T, Bowman J, et al: Estramustine versus conventional estrogen hormones in the initial treatment of highly or moderately differentiated prostate carcinoma: a randomised study. Scand J Urol Nephrol (suppl) 55: 143–145, 1980.
- 26 Henriksson P, Edhag O: Orchidectomy versus estrogen for prostate cancer. B M J 293: 413–415, 1986.
- 27 Haapiainen R, Rannika S, Ruutu: Orchidectony versus estrogen in the treatment of advanced prostatic cancer. B J Urol 67: 184–187, 1991.
- 28 Eisen M, Napp HE, Vock R: Thrombocyten-aggregation-shemmung bei oestrogen-behandelten prostata-carcinoma-patienten. Urologe A14: 132–136, 1975.
- 29 Vahlensieck W, Wegner G: Continuous versus intermittent oral therapy with Estramustine phosphate (Estracyt). Scand J Urol Nephrol (suppl) 55: 147–149, 1980.
- 30
Akakura K,
Bruchovsky N,
Goldenberg SL, et al:
Effects of intermittent androgen suppression on androgen-dependent tumors.
Cancer
71: 2782–2790,
1993.
10.1002/1097-0142(19930501)71:9<2782::AID-CNCR2820710916>3.0.CO;2-Z PubMed Web of Science® Google Scholar
- 31 Veterans Administration Cooperative Urological Research Group: protocol for a cooperative study of carcinoma of the prostate IV. Sept 1975 (Unpublished).
